ResMed Accounts Receivable increased by 1.3% to $998.84M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $907.83M to $998.84M. Over 4 years (FY 2021 to FY 2025), Accounts Receivable shows an upward trend with a 11.2% CAGR.
An increase relative to sales may signal slowing collections or credit risk, while a decrease suggests efficient cash conversion.
The total amount of credit extended to customers and channel partners for products sold or services rendered, minus an a...
Typically scales with revenue growth; however, companies with strong direct-to-consumer channels may have lower receivables relative to those relying on third-party distributors.
accounts_receivable_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $614.29M | $575.55M | $526.04M | $508.58M | $575.95M | $620.48M | $672.27M | $686.26M | $704.91M | $692.39M | $729.74M | $779.27M | $837.28M | $811.20M | $859.94M | $907.83M | $939.49M | $907.27M | $985.63M | $998.84M |
| QoQ Change | — | -6.3% | -8.6% | -3.3% | +13.2% | +7.7% | +8.3% | +2.1% | +2.7% | -1.8% | +5.4% | +6.8% | +7.4% | -3.1% | +6.0% | +5.6% | +3.5% | -3.4% | +8.6% | +1.3% |
| YoY Change | — | — | — | — | -6.2% | +7.8% | +27.8% | +34.9% | +22.4% | +11.6% | +8.5% | +13.6% | +18.8% | +17.2% | +17.8% | +16.5% | +12.2% | +11.8% | +14.6% | +10.0% |